MTOR and neoplasm with perivascular epithelioid cell differentiation: A study by Sanfilippo et al. reported the efficacy of various systemic therapies against PEComas: gemcitabine (ORR 20%, with mPFS of 3.4 months), anthracyclines (ORR 13%, with mPFS of 3.2 months), and antiangiogenic agents (ORR 8.3%, with mPFS of 5.4 months); mTOR inhibition was still shown to be the most effective (ORR of 41%, with a mPFS of 9 months) [14].